Mucosal NOD2 expression and NF-kappaB activation in pediatric Crohn's disease

Inflamm Bowel Dis. 2008 Mar;14(3):295-302. doi: 10.1002/ibd.20332.

Abstract

Background: Recent advances in the pathogenesis of Crohn's disease (CD) have suggested that an aberrant innate immune response initiates the cascade of events leading to T-cell activation and to disease development. NOD2 protein, which is mainly expressed by innate immunity cells, appears to play a key role against bacteria by triggering a host defense response through the activation of the transcriptor factor NF-kappaB and a consequent proinflammatory cytokine production. The present study was aimed at investigating the expression and activity of NOD2, NF-kappaB, and of 2 proinflammatory cytokines, TNFalpha and IL-1beta, in mucosal biopsies of CD affected children compared to healthy controls.

Methods: In all, 22 children with active CD and 10 matched controls were entered in the study. mRNA and protein expressions were detected using reverse-transcriptase polymerase chain reaction (RT-PCR) and Western blot; NF-kappaB binding activity was assessed by electromobility gel shift assay (EMSA).

Results: NOD2 and IL-1beta mRNAs were upregulated in CD children. Protein levels of NOD2, TNFalpha, and nuclear NF-kappaB, as well as the binding activity of NF-kappaB to a consensus DNA sequence, were significantly increased in inflamed mucosa of patients as compared to controls. Moreover, NF-kappaB activity was strongly upregulated in patients also when bound to the NOD2 promoter site. No difference was seen between patients and controls when NF-kappaB binding activity was determined in the uninflamed tissue.

Conclusions: This study suggests that altered mechanisms regulating NOD2 induction, NF-kappaB activation and cytokine production may contribute to dysregulate the innate immune response underlying pediatric CD.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / therapeutic use
  • Biopsy
  • Blotting, Western
  • Child
  • Colonoscopy
  • Crohn Disease / drug therapy
  • Crohn Disease / genetics
  • Crohn Disease / metabolism*
  • Electrophoretic Mobility Shift Assay
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents / therapeutic use
  • Gene Expression*
  • Genotype
  • Humans
  • Immunity, Innate / genetics
  • Infliximab
  • Interleukin-1beta / biosynthesis
  • Interleukin-1beta / drug effects
  • Interleukin-1beta / genetics
  • Intestinal Mucosa / metabolism*
  • Intestinal Mucosa / pathology
  • Male
  • NF-kappa B / drug effects
  • NF-kappa B / genetics
  • NF-kappa B / metabolism*
  • Nod2 Signaling Adaptor Protein / biosynthesis
  • Nod2 Signaling Adaptor Protein / genetics*
  • Prognosis
  • RNA, Messenger / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Severity of Illness Index
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Interleukin-1beta
  • NF-kappa B
  • NOD2 protein, human
  • Nod2 Signaling Adaptor Protein
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Infliximab